The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.

The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.

<h4>Background</h4>Cardiovascular disease is a major cause of morbidity and mortality in COPD patients. Systemic inflammation associated with COPD, is often hypothesised as a causal factor. p38 mitogen-activated protein kinases play a key role in the inflammatory pathogenesis of COPD and...

Full description

Bibliographic Details
Main Authors: Marie Fisk, Joseph Cheriyan, Divya Mohan, Julia Forman, Kaisa M Mäki-Petäjä, Carmel M McEniery, Jonathan Fuld, James H F Rudd, Nicholas S Hopkinson, David A Lomas, John R Cockcroft, Ruth Tal-Singer, Michael I Polkey, Ian B Wilkinson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0194197

Internet

https://doi.org/10.1371/journal.pone.0194197

Similar Items